Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MaxCyte, Inc.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
- Medical Devices
- Drug Delivery
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- CARMA Cell Therapies